{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-011106","form_type":"8-K","ticker":"SGHT","cik":"0001531177","company_name":"Sight Sciences, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.350418+00:00","generated_at":"2026-05-16T10:39:33.746231+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sight Sciences reports Q4 2025 revenue up 7% YoY; FY 2025 revenue down 3% YoY","bullets":["Q4 2025 total revenue $20.3M-$20.4M, +7% vs Q4 2024; Surgical Glaucoma +5%, Dry Eye +130%.","Full year 2025 revenue $77.3M-$77.4M, down 3% vs 2024; Surgical Glaucoma flat, Dry Eye ~$1.6M (from $4.0M).","Cash and equivalents ~$92M; Q4 cash burn ~$0.4M, FY cash used ~$28M.","Management reiterates path to cash flow breakeven without additional equity; complete results expected March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-011106","json":"https://secwatch.observer/filing/0001193125-26-011106.json","markdown":"https://secwatch.observer/filing/0001193125-26-011106.md","text":"https://secwatch.observer/filing/0001193125-26-011106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/0001193125-26-011106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1531177/000119312526011106/sght-20260113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:39:33.746231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}